1. House dust mite models: Will they translate clinically as a superior model of asthma? 
Jonathan E. Phillips, PhD, Ruoqi Peng, MD, Paul Harris, BS, Lisa Burns, BS, Lorena Renteria, Lennart K.A. Lundblad, PhD, Jay S. Fine, PhD, Carla M.T. Bauer, PhD, Christopher S. Stevenson, PhD 
Journal of Allergy and Clinical Immunology 
Volume 132, Issue 1, Pages (July 2013)
DOI: /j.jaci
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Intravenous administration of HDM to HDM-sensitized mice increased respiratory system resistance (R) (A) and mouse mast cell protease 1 (mMCP-1) levels in lavage fluid (B). C, Percent peak increase over baseline R to intravenous (i.v.) saline, ovalbumin (OVA), and dose-response to HDM in HDM sensitized and nonsensitized mice. Data are presented as mean ± SEM (n = 4-8). BALF, Bronchoalveolar lavage fluid. *P < .05.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
A, R increased after 3 weeks, but not 4 days, of HDM treatment and was inhibited by methysergide (10 mg/kg, i.p.) and reduced in mast cell–deficient mice (B). Total cells recovered in the bronchoalveolar lavage (BAL) fluid (C) increased after 4 days and 3 weeks of HDM treatment. Data are presented as mean ± SEM (n = 4-8). i.n., Intranasally; i.p., intraperitoneal.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions